



***Onxeo attends InvestorDagen 2014,
the largest Danish private investor event
Great success for its first participation***

Paris (France), Copenhagen (Denmark), September 19, 2014 –Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen - ONXEO), an innovative company specialized in the development of drugs for orphan oncology diseases, attended InvestorDagen 2014, held in Copenhagen on September 17, 2014.

InvestorDagen is hosted by the Danish Shareholders' Association, an association with 12,000 members. With around 2,500 participants, InvestorDagen is the largest event for private investors in Denmark.

For its first participation, Onxeo's management team gave a presentation of the Company, its key strengths, its strategy based on advanced orphan oncology products and the mid-term news flow which is expected to drive value and future growth. This event was also the opportunity to meet and exchange with the participating Danish investors who were many to visit Onxeo's booth, making a great success of this meeting.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference". The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key products at advanced development stage are:

Livatag[®] (Doxorubicin Transdrug[™]): Phase III in hepatocellular carcinoma

Validive[®] (Clonidine Lauriad[®]): Phase II in severe oral mucositis

Beleodaq[®] (belinostat): Registered and available in the USA for peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website (www.onxeo.com).

Contacts :

Judith Greciet, CEO
j.greciet@onxeo.com
+33 1 45 58 76 00

Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP
caroline@alizerp.com / scolin@alizerp.com
+33 6 64 18 99 59 / +33 6 31 13 76 20